Parakkal Deepak, MBBS, MS

Parakkal Deepak, MBBS, MS

Associate Professor of Medicine

Related Links


  • IBD Fellowship: Mayo Clinic, Rochester, MN (2017)
  • Fellowship: Mayo Clinic, Rochester, MN (2016)
  • Residency: University of Chicago (NorthShore), Chicago, IL (2011)
  • Residency: India Institute of Medical Sciences (2007)
  • MBBS: India Institute of Medical Sciences (2004)

Clinical Interests

Crohn’s disease, ulcerative colitis, pouchitis, celiac disease, checkpoint inhibitor induced colitis, microscopic colitis.

My clinical expertise is in the diagnosis and management of complex IBD with the overarching focus on improving the precision of medical therapy in IBD, focusing on the right patient, the right drug and the right dose, to maximize efficacy and limit side-effects.

Research Interests

My goal is to become a leader in research that allows personalized precision care for IBD patients to optimize outcomes and minimize treatment related side effects. My current research focus funded through industry grant and the American College of Gastroenterology Junior Faculty Development Award, has been on utilizing non-invasive methodologies for assessment of disease activity and response to medical therapy in Crohn’s disease. I work in close collaboration with expert abdominal radiologists at Mallinckrodt Institute of Radiology as part of the Washington University IBD-Radiology Collaborative Group. In particular, my research has explored transmural response assessed with computed tomography or magnetic resonance enterography as a treatment target in small bowel Crohn’s disease. I am also involved in novel biomarker discovery studies using a multiomics (radiomics, proteomics and metabolomic) approach towards early prediction of non-response with biologics in Crohn’s disease in blood and stool. I am also co-Principal Investigator at our site of the Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC-IBD) cohort of the Crohn’s and Colitis Foundation. 

I have additionally explored body composition analysis as a predictor of long-term outcomes and a marker of response in small bowel Crohn’s disease. I am also exploring fatty liver disease in patients with Crohn’s disease using cutting edge technologies in magnetic resonance imaging. Additional collaborations include working with the computational group at the Informatics Institute at Washington University in St. Louis in using machine learning approaches to solve clinically meaningful questions in IBD in the inpatient and outpatient data-sets.